|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����� |
|
Ƥ���� |
|
ҩ��ѧ |
| ��������������� | |
|
����� |
|
֣���� |
| PubMed | |
|
Article by |
|
Article by |
�������ٴ�ǰҩ���ٴ�ҩ��������
�����, ֣����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
�������һ�ִ�ͳ�Ŀ�����,��Ƥ������Ҫ������粡������,���Դ�20����50����������������Ƥ����������Ч��,�ٴ����ѱ����ڶ��ַǸ�Ⱦ����֢��Ƥ���������ƺ�Ԥ��.�ֶ�����������ҩЧѧ�����û��ơ�ҩ������ѧ��ѪҺϵͳ�Ķ��Է�Ӧ������Ƥ�������ٴ�Ӧ���о����½�չ�����˸���.
[2] Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone:inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol, 1997,62(6):827-836.
[3] Modschiedler K, Weller M, Worl P,et al. Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Dermatol Res, 2000,292(1): 32-36.
[4] Mahmud R, Tingle MD, Maggs JL, et al. Structural basis for the haemotoxicity of dapsone: the importance of the sulphonyl group. Toxicology,1997,117(1):1-11.
[5] Wozel G, Blasum C, Winter C, et al. Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study.Inflamm Res, 1997,46(10):420-422.
[6] Mirochnick M, Cooper E, McIntosh K, et al. Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. Antimicrob Agents Chemother, 1999,43 (11): 2586-2591.
[7] Tingle MD, Mahmud R, Maggs JL, et al. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther,1997,283(2): 817-823.
[8] Lu M, Poloyac SM, McNamara PJ, et al. The effect of pregnenolone 16alpha-carbonitrile on the pharmacokinetics and metabolism of dapsone in rats. J Pharm Pharmacol, 1999,51(7): 803-810.
[9] Guo R, Thormann W, Lauterberg B. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. Chin Med J (Engl), 1996, 109 (12): 933-936.
[10] Coleman MD, Pahal KK, Gardiner JM. The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro. J Pharm Pharacol, 1996,48(4):401-406.
[11] McMillan DC, Simson JV, Budinsky RA, et al. Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulfhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. J Pharmacol Exp Ther, 1995,274 (1): 540-547.
[12] McMillan DC, Jensen CB, Jollow DJ. Role of lipid peroxidation in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther, 1998, 287 (3):868-876.
[13] Cicooli L, Ferrali M, Rossi V, et al. Hemolytic drugs aniline and dapsone induce iron release in erythrocytes and increase the free iron pool in spleen and liver. Toxicol Lett, 1999,110(1-2):57-66.
[14] Ahmadi M, Khalaf LF, Smith HJ, et al. A dapsone-induced blood dyscrasia in the mouse: evidence for the role of an active metabolite. J Pharm Pharmacol, 1996,48(2): 228-232.
[15] Wolf R, Tuzun B, Tuzun Y,et al. Dapson: unapproved uses or indications.Clin Dermatol, 2000,18: 37-53.
[16] Ghate JV, Jorizzo JL. Behcet's disease and complex aphthosis. J Am Acad Dermatol, 1999,40(1):1-18.
[17] Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1999,88(2):159-163.
[18] Mobini N, Nagarwalla N, Ahmed AR. Oral pemphigoid. Subset of cicatricial pemphigoid? Oral Surg Oral Med Oral Pathol Oral Radiol Endod,1998,85(1): 37-43.
[19] Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin, 2001,19(1): 79-86.
[20] Kulthanan K, Akaraphanth R, Piamphongsant T, et al. Linear IgA bullous dermatosis of childhood: a long-term study. J Med Assoc Thai, 1999,82(7): 707-712.
[21] Porneuf M, Duterque M, Sotto A, et al. Unusual erythema elevatum diutinum with fibrohistocytic proliferation. Br J Dermatol, 1996, 134 (6):1131-1134.
[22] Bohm I, Bruns A, Schupp G, et al. ANCA-positive lupus erythematodes profounds, Successful therapy with low dosage dapsone. Hautarzt, 1998, 49:403-407.
[23] Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia:Response to dapsone. J Am Acad Dermatol, 1996,35(2 Pt 2):313-315.
[24] Nishina M, Saito E, Kinoshita M. Correction of severe leukocytopenia and thrombocytopenia in systemic lupus erythematosus by treatment with dapsone. J Rheumatol, 1997,24(4): 811-812.
[25] Erdi H,Anadolu R,Piskin G,et al. Malignant pyoderma:a clinical variant of pyoderma gangrenosom. Int J Dermatol, 1996,35(11): 811-813.
[26] Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis, 1998,27 (1):191-204.
[27] Ma L, Borio L, Masure H, et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis, 1999,180(6):1969-1978.
[28] Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura:a report of 66 cases. Br J Haematol,1997,97: 336-339.
[29] Nishigaki F, Tsujimoto S, Inami M, et al. Effects of a novel pyridysulphonyl thiazole derivative, FR115092, on autoimmune and mitomycin C-induced thrombocytopenia in mice. J Pharm Pharmcol, 1999,51(7): 857-865.
[30] Ahmadi M, Khalaf LF, Smith HJ, et al. A dapsone-induced blood dyscrasia in the mouse:evidence for the role of an active metabolite. J Pharm Pharmacol, 1996,48(2): 228-32.